Symbiosis Pharmaceutical Services has launched new in-house analytical and microbiological capabilities to enable testing of small molecule, biological, and Advanced Therapeutic Medicinal Products (ATMP) biopharmaceuticals following a $1.25 million investment. The company has added 3,600 ft² of new space, significantly expanding its existing GMP operational footprint at the Stirling Innovation Park site in Scotland. 
 
Fully approved by the UK Regulatory Agency the MHRA, the expansion strategically enhances the company’s core sterile fill/finish manufacturing service and provides an extensive in-house Quality Control (QC) function to support the products aseptically manufactured by Symbiosis. 
 
The new labs will offer microbiology and analytical testing capabilities, and sterility testing. In addition, Symbiosis will introduce temperature and humidity-controlled stability storage capabilities in support of ICH pharmaceutical stability studies. 
 
Symbiosis’ strategic projects director Alison Clayton said: “We are delighted that Symbiosis’ analytical testing laboratories and QC function are now operational and fully approved by the MHRA. This project demanded a great team effort from both Symbiosis and principal project contractors Olison Ltd. to ensure the design, build and subsequent qualification activities were undertaken efficiently, with regulatory compliance, and with the development of an underlying quality system at the heart of the project management ethos.”
 
CEO Colin MacKay added: “The new laboratories that we have built will further propel the continued strategic growth of Symbiosis by adding value to the drug development projects which our clients entrust to us. We are proud to combine an existing world class quality system with brand new analytical service laboratories which will serve to shorten our clients’ drug development timelines and bring them value by getting their medicines to patients more quickly.”